Thrivent Financial for Lutherans Has $88.43 Million Position in Haemonetics Co. (NYSE:HAE)

Thrivent Financial for Lutherans boosted its holdings in Haemonetics Co. (NYSE:HAE) by 29.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,100,183 shares of the medical instruments supplier’s stock after buying an additional 250,833 shares during the quarter. Thrivent Financial for Lutherans owned approximately 2.15% of Haemonetics worth $88,433,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Quarry LP acquired a new position in shares of Haemonetics during the second quarter worth $39,000. Covestor Ltd lifted its holdings in Haemonetics by 184.8% during the 1st quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock worth $58,000 after buying an additional 438 shares during the period. Daiwa Securities Group Inc. bought a new stake in shares of Haemonetics in the 2nd quarter valued at about $82,000. Canada Pension Plan Investment Board acquired a new stake in shares of Haemonetics in the second quarter valued at about $83,000. Finally, EntryPoint Capital LLC bought a new position in shares of Haemonetics during the first quarter worth about $86,000. 99.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have issued reports on HAE shares. CL King assumed coverage on shares of Haemonetics in a report on Friday, September 13th. They set a “buy” rating and a $116.00 price target for the company. Raymond James raised shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 target price for the company in a research note on Friday, November 8th. Barrington Research reaffirmed an “outperform” rating and set a $108.00 price target on shares of Haemonetics in a research report on Friday, November 8th. Needham & Company LLC reissued a “buy” rating and issued a $112.00 price objective on shares of Haemonetics in a research note on Friday. Finally, Bank of America began coverage on Haemonetics in a research note on Wednesday, September 11th. They set a “neutral” rating and a $85.00 target price for the company. Three research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $107.88.

Haemonetics Trading Down 1.7 %

NYSE HAE opened at $89.22 on Monday. The stock has a market cap of $4.48 billion, a P/E ratio of 37.02, a price-to-earnings-growth ratio of 1.39 and a beta of 0.32. Haemonetics Co. has a fifty-two week low of $70.25 and a fifty-two week high of $97.97. The stock has a 50 day simple moving average of $77.55 and a two-hundred day simple moving average of $82.62. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $1.09 by $0.03. The firm had revenue of $345.50 million for the quarter, compared to analyst estimates of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The company’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.99 EPS. On average, analysts forecast that Haemonetics Co. will post 4.59 earnings per share for the current year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.